Chronic Heart Failure Monitoring NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 All of the studies involved repeated BNP or NT-proBNP (together called NP) biomarker testing. Treatment algorithms varied, with some treating to an absolute target, others aiming for a personal target best on percentage drop of levels. These were compared against clinical monitoring in the other study arm. No relevant studies comparing usual care with routine cardiac imaging, troponin, or combinations of different biomarkers were identified. Table 85: Summary of systematic review included in the review Study Intervention and comparison (in HF clinic unless stated otherwise) Population Included data Troughton (Brunner-la ) Troughton IPD NP-guided therapy vs Clinically-guided therapy (3-24 months) Stratified by LVEF status. Age mean (SD): Studies included in IPD: BATTLESCARRED, Berger 2010, Christchurch pilot, PRIMA, PROTECT, SIGNAL-HF, TIME- CHF*, UPSTEP *the HFpEF arm of TIME-CHF is included in Brunner La Rocca, but not the original meta-analysis ACEi/ARB: Angiotensin converting enzyme inhibitor and/or Aldosterone receptor blocker, BB: Beta-blocker, IV: Intravenous therapy, NP: natriuretic peptides including BNP and NT-proBNP Table 86: Summary of primary studies included in the review Study Intervention and comparison (in HF clinic unless stated otherwise) Population Outcomes Comments BATTLESCARRE D trial: Lainchbury (Lainchbury ) NP monitoring: Therapy increased to achieve clinical and NP target (congestion score<2 Clinical monitoring: Therapy increased to meet target months No protocol: Discharged to primary care Age > 18 mean: HF-admission Elevated NP (NT- proBNP > 50 pmol/L) Troughton IPD: Mortality Recruited from hospital Chronic Heart Failure Monitoring NICE 2018. All rights reserved. Subject to Notice of rights. 